InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
For 40 years, weâve worked at the intersection of health care and information te...
For 40 years, weâve worked at the intersectio...
Quadrant Biosciences is an epigenetic diagnostics company with a focus on the earl...
Quadrant Biosciences is an epigenetic diagnosti...
Dentsply Sirona is the worldâs largest manufacturer of professional dental produ...
Dentsply Sirona is the worldâs largest manufa...
Surface Oncology is an immuno-oncology company on a mission to break through and d...
Surface Oncology is an immuno-oncology company ...
Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company ...
Iterum Therapeutics plc is an Ireland-based cli...
Aileron Therapeutics is a clinical stage company discovering and developing novel ...
Aileron Therapeutics is a clinical stage compan...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceut...
Hutchison China MediTech Limited, known as Chi-...
Caladrius is a clinical-stage biopharmaceutical company committed to the developme...
Caladrius is a clinical-stage biopharmaceutical...
Exicure, Inc. is a clinical stage biotechnology company developing a new class of ...
Exicure, Inc. is a clinical stage biotechnology...
Join the National Investor Network and get the latest information with your interests in mind.